AACR China Voice | Qilu Pharmaceutical Showcases Multiple Innovative Breakthroughs at AACR, Driving Global Advances in Oncology Through Originative Innovation

AACR China Voice | Qilu Pharmaceutical Showcases Multiple Innovative Breakthroughs at AACR, Driving Global Advances in Oncology Through Originative Innovation

From April 17 to 22, 2026, the Annual Meeting of the American Association for Cancer Research—one of the most influential events in global oncology—was held. At this premier scientific forum, the R&D team of Qilu Pharmaceutical presented a series of independently developed innovative research achievements spanning cutting-edge fields such as antibody–drug conjugates (ADCs), bispecific and trispecific antibodies, and small-molecule therapies.
AACR China Voice | Professor Tao Zhu: First-in-Human Study of CLDN6 ADC QLS5132 Demonstrates Promising Efficacy and Safety, Opening New Directions for Platinum-Resistant Ovarian Cancer

AACR China Voice | Professor Tao Zhu: First-in-Human Study of CLDN6 ADC QLS5132 Demonstrates Promising Efficacy and Safety, Opening New Directions for Platinum-Resistant Ovarian Cancer

Platinum-resistant recurrent ovarian cancer (PROC) remains a major clinical challenge, characterized by poor overall prognosis, limited effective treatment options, high unmet medical need, and suboptimal safety profiles. Innovative treatment strategies are urgently needed.
Professor Yu Wang: Innovations and Advances in Transplantation Strategies for AML

Professor Yu Wang: Innovations and Advances in Transplantation Strategies for AML

Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from myeloid stem cells, characterized by significant biological diversity and generally poor prognosis. The global disease burden of AML continues to rise, with the age-standardized incidence increasing by 87.3% between 1990 and 2021, underscoring the urgent need for improved therapeutic strategies.